| Schedule of other Income |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Eight Months Ended
June 30, |
|
|
Years Ended
October 31, |
|
| |
|
2026 |
|
|
2025 |
|
|
2024 |
|
| Other income |
|
|
|
|
|
|
|
|
|
|
|
|
| Gain on write-off of advances payable to former officer and settlement on outstanding payables (see Note 16) |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
221,000 |
|
| Gain, net of obligations in connection with termination of supply agreement (see Note 15) |
|
|
- |
|
|
|
- |
|
|
|
168,000 |
|
| Gain on sale of Exotropin interests |
|
|
390,000 |
|
|
|
- |
|
|
|
- |
|
| Resolution and settlement of long outstanding payables |
|
|
- |
|
|
|
19,000 |
|
|
|
176,000 |
|
| Commissions on sales of Exotropin products |
|
|
- |
|
|
|
61,000 |
|
|
|
87,000 |
|
| Proceeds from insurance claim |
|
|
|
|
|
|
|
|
|
|
89,000 |
|
| Other |
|
|
27,000 |
|
|
|
21,000 |
|
|
|
10,000 |
|
| Total |
|
$ |
417,000 |
|
|
$ |
101,000 |
|
|
$ |
751,000 |
|